维普期刊资源整合服务平台（V6.5）

39篇 您的检索式：作者名="Sedlinsky"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy?显示文摘Patients with long-term type 1 and type 2 diabetes mellitus(DM) can develop skeletal complications or 'diabetic osteopathy'. These include osteopenia, osteoporosis and an increased incidence of low-stress fractures. In this context, it is important to evaluate whether current anti-diabetic treatments can secondarily affect bone metabolism. Adenosine monophosphateactivated protein kinase(AMPK) modulates multiple metabolic pathways and acts as a sensor of the cellular energy status; recent evidence suggests a critical role for AMPK in bone homeostasis. In addition, AMPK activation is believed to mediate most clinical effects of the insulin-sensitizer metformin. Over the past decade, several research groups have investigated the effects of metformin on bone, providing a considerable body of pre-clinical(in vitro, ex vivo and in vivo) as well as clinical evidence for an anabolic action of metformin on bone. However, two caveats should be kept in mind when considering metformin treatment for a patient with type 2 DM at risk for diabetic osteopathy. In the first place, metformin should probably not be considered an antiosteoporotic drug; it is an insulin sensitizer with proven macrovascular benefits that can secondarily improve bone metabolism in the context of DM. Secondly, we are still awaiting the results of randomized placebo-controlled studies in humans that evaluate the effects of metformin on bone metabolism as a primary endpoint.	Antonio Desmond McCarthy Ana María Cortizo Claudia Sedlinsky	2016	World Journal of Diabetes2016，7，6：	9
2	Insulin-deficient diabetes-induced bone microarchitecture alterations are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: Preventive effects of metformin显示文摘	María José Tolosa Sara Rocío Chuguransky Claudia Sedlinsky León Schurman Antonio Desmond McCarthy María Silvina Molinuevo Ana María Cortizo	2013	Diabetes Research and Clinical Practice2013，，2：	1
3	Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture显示文摘	Cortizo A M Sedlinsky C McCarthy A D Blanco A Schurman L	2006	Eur J Pharmacol2006，536，：	1
4	Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats显示文摘	Claudia Sedlinsky María Silvina Molinuevo Ana María Cortizo María José Tolosa Juan Ignacio Felice María Laura Sbaraglini Leon Schurman Antonio Desmond McCarthy	2011	European Journal of Pharmacology2011，，3：	1
5	Saxagliptin affects long-bone microarchitecture and decreases the osteogenic potential of bone marrow stromal cells显示文摘	Sbaraglini ML Molinuevo MS Sedlinsky C	2014	Eur J Pharmacol2014，727，：	1
6	Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture显示文摘	Cortizo A M Sedlinsky C McC arthy A D	2006	Eur J Pharmacol2006，536，12：	1
7	Metformin reverts deleterious effects of advanced glycation end-products(AGEs)on osteoblastic cells显示文摘	Schurman L McC arthy A D Sedlinsky C	2008	Exp Clin Endocrinol Diabetes2008，116，6：	1
8	Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture显示文摘	Cortizo AM Sedlinsky C McCarthy AD	2006	Eur J Pharmacol2006，536，12：	1
9	Osteogenic actions of the anti diabetic drug metformin on osteoblasts in culture显示文摘	Cortizo AM Sedlinsky C McCarthy AD	2006	Eur J Pharmacol2006，，536：	1
10	Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture显示文摘	Cortizo AM Sedlinsky C McCarthy AD	2006	Eur J Pharmacol2006，536，：	1
11	Osteogenic actions of the anti-diabetic drug Metformin on osteoblasts irl culture 显示文摘	Cortizo AM Sedlinsky C McCarthy AD	2006	European Journal of Pharmacology2006，536，12：	1
12	Saxagliptin affects long-bone microarchitecture and decreases the osteogenic potential of bone marrow stromal cells显示文摘	María Laura Sbaraglini María Silvina Molinuevo Claudia Sedlinsky León Schurman Antonio Desmond McCarthy	2014	European Journal of Pharmacology2014，，：	1
13	Osteogenie actions of the anti - diabetic drug Metformin on osteoblasts in culture 显示文摘	Cortizo AM Sedlinsky C McCarthy AD	2006	European Journal of Pharmacology2006，536，12：	1
14	Osteogehic actions of the anti-diabetic drugMetformin on osteoblasts in culture显示文摘	Sedlinsky C McCarthy AD	2006	European Journal of Pharmacology2006，536，12：	1
15	Insulin-deficient diabetes-induced bone microarchitecture alterations are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: preventive effects of metformin显示文摘	Tolosa MJ Chuguransky SR Sedlinsky C	2013	Diabetes Res Clin Pract2013，101，2：	1
16	Osteogenic actions of the antidiabetic drug Metformin on osteoblasts in culture显示文摘	Cortizo AM Sedlinsky C McCarthy AD	2006	European Journal of Pharmacology2006，536，12：	1
17	Osteogenic actions of the anti diabetic drug metformin on osteoblasts in culture 显示文摘	Cortizo AM Sedlinsky C McCarthy AD	2006	Eur J Pharmacol2006，536，12：	1
18	Metformin reverts deleterious effects of advancedglycation end-Products (AGEs) on osteoblastic cells显示文摘	Schurman L McCarthy AD Sedlinsky C	2008	Exp Clin Endocrinol Diabetes2008，116，6：	1
19	Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture 显示文摘	Cortizo AM Sedlinsky C McCarthy AD	2006	EurJ Pharmacol2006，536，：	1
20	Osteogenic actions of the anti-diabetic drug met- formin on osteoblasts in culture显示文摘	Cortizo AM Sedlinsky C McCarthy AD	2006	Eur J Pharma- col2006，536，12：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示